Basic Information
UBRETID TABLET 5 mg
TABLET
Regulatory Information
SIN02915P
May 22, 1989
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 4, 2025
XN07AA03
Company Information
CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED
CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED
Active Ingredients
Strength: 5 mg
Detailed Information
Contraindications
**Contraindications** UBRETID® must not be used in: Hypersensitivity to the active substance or to any of the excipients as well as bromine allergy, severe vagotonia (dominance of the parasympathetic part of the autonomic-vegetative-nervous system) accompanied by low blood pressure, slow heart rate, hyperacidity, hyperperistalsis of intestine and stomach, increased salivation, peripheral circulatory disturbances, mechanical obstruction to urinary outflow, obstructive ileus, stenosis or spasms in the intestinal tract, in the biliary ducts and urinary passages, gastric ulcers, enteritis; very low blood pressure, increased muscular tone, muscular spasm (tetany), falling sickness (epilepsy), shaking palsy (Parkinson’s disease), postoperative shock and circulatory crises; non-treated cardiac insufficiency, cardiac infarction, congestive heart failure, recent myocardial infarction, cardiac arrhythmias, in particular bradycardia and AV block, bronchial asthma, Iritis, myotonia, and thyrotoxicosis.
Indication Information
**Indications** Functional insufficiency of the vesical sphincteral apparatus Hypotonia of the urinary bladder Chronic hypotonic constipation and megacolon In various neurological indications (peripheral paralyses of the striated muscles, myasthenia gravis pseudoparalytica) a functional improvement can be obtained.